ExiVex BioPharma
Developer of a dual-chamber intranasal delivery platform that mixes drug and absorption-enhancing excipient at the moment of actuation to enable rapid systemic uptake. Lead program is an intranasal naloxone product in IND-enabling development with FDA-aligned 505(b)(2) regulatory strategy, a PCT patent filed April 2026, and IRB-approved exploratory human PK data showing rapid onset and early exposure approaching an IV reference.
Industries
N/A
Nr. of Employees
small (1-50)
Products
EMRX-101 (intranasal naloxone dual-chamber delivery)
Dual-chamber intranasal naloxone product designed to mix drug and absorption-enhancing excipient at actuation to produce rapid systemic exposure; IND-enabling stage with exploratory human PK data showing rapid onset and early exposure approaching an IV reference.
EMRX-102 (ketorolac + sumatriptan dual-mechanism intranasal)
Feasibility-stage program applying the dual-chamber platform to rapid-onset treatment for acute migraine via combined agents.
EMRX-103 (benzodiazepine intranasal rescue)
Concept-stage program for acute seizure rescue using the dual-chamber intranasal platform.
EMRX-104 (antiemetic intranasal)
Concept-stage intranasal antiemetic program intended for emergency and post-operative nausea control.
EMRX-105 (nerve agent countermeasure intranasal)
Concept-stage program combining atropine and pralidoxime for nerve agent countermeasure use; external funding engagements (e.g., BARDA/DoD) indicated.
EMRX-101
An investigational emergency-grade intranasal naloxone rescue product engineered using a proprietary dual-chamber platform to achieve rapid bioavailability approaching IV speeds in seconds without injection.
EMRX-101 (intranasal naloxone dual-chamber delivery)
Dual-chamber intranasal naloxone product designed to mix drug and absorption-enhancing excipient at actuation to produce rapid systemic exposure; IND-enabling stage with exploratory human PK data showing rapid onset and early exposure approaching an IV reference.
EMRX-102 (ketorolac + sumatriptan dual-mechanism intranasal)
Feasibility-stage program applying the dual-chamber platform to rapid-onset treatment for acute migraine via combined agents.
EMRX-103 (benzodiazepine intranasal rescue)
Concept-stage program for acute seizure rescue using the dual-chamber intranasal platform.
EMRX-104 (antiemetic intranasal)
Concept-stage intranasal antiemetic program intended for emergency and post-operative nausea control.
EMRX-105 (nerve agent countermeasure intranasal)
Concept-stage program combining atropine and pralidoxime for nerve agent countermeasure use; external funding engagements (e.g., BARDA/DoD) indicated.
EMRX-101
An investigational emergency-grade intranasal naloxone rescue product engineered using a proprietary dual-chamber platform to achieve rapid bioavailability approaching IV speeds in seconds without injection.
Services
Engagements with investors, pharma partners, CDMOs and grant collaborators for co-development, licensing, contract manufacturing, and non-dilutive funding.
Provision of clinical PK study report, regulatory meeting minutes, IP summary, and financial model to qualified investors and partners under NDA.
Engagements with investors, pharma partners, CDMOs and grant collaborators for co-development, licensing, contract manufacturing, and non-dilutive funding.
Provision of clinical PK study report, regulatory meeting minutes, IP summary, and financial model to qualified investors and partners under NDA.
Expertise Areas
- Intranasal drug delivery development
- Clinical pharmacokinetics and PK study execution
- Device engineering for drug delivery
- Formulation chemistry and pH-optimization
Key Technologies
- Dual-chamber intranasal actuator
- Point-of-use formulation mixing
- Venturi atomization
- pH-optimized absorption-enhancing excipients
News & Updates
Press release reporting exploratory PK study results in healthy volunteers (n=13 for lead cohort) showing rapid onset and increased early exposure versus a single intranasal comparator.
Press release announcing IRB approval for a randomized crossover PK study comparing the intranasal product to a listed intranasal comparator.
Press release announcing presentation at an investor conference and related investor-facing events.
Press release announcing a Regulation Crowdfunding private placement offering to broaden the investor base.
Investor update covering the dual-chamber platform, PK data, regulatory pathway, and company milestones.
Press release reporting exploratory PK study results in healthy volunteers (n=13 for lead cohort) showing rapid onset and increased early exposure versus a single intranasal comparator.
Press release announcing IRB approval for a randomized crossover PK study comparing the intranasal product to a listed intranasal comparator.
Press release announcing presentation at an investor conference and related investor-facing events.
Press release announcing a Regulation Crowdfunding private placement offering to broaden the investor base.
Investor update covering the dual-chamber platform, PK data, regulatory pathway, and company milestones.